Teva Pharmaceutical Industries (TEVA) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $4.7 billion.
- Teva Pharmaceutical Industries' Accumulated Depreciation & Amortization rose 718.82% to $4.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.7 billion, marking a year-over-year increase of 718.82%. This contributed to the annual value of $4.7 billion for FY2025, which is 718.82% up from last year.
- Latest data reveals that Teva Pharmaceutical Industries reported Accumulated Depreciation & Amortization of $4.7 billion as of Q4 2025, which was up 718.82% from $4.4 billion recorded in Q4 2024.
- In the past 5 years, Teva Pharmaceutical Industries' Accumulated Depreciation & Amortization ranged from a high of $5.6 billion in Q4 2023 and a low of $4.4 billion during Q4 2024
- Its 5-year average for Accumulated Depreciation & Amortization is $5.1 billion, with a median of $5.2 billion in 2021.
- In the last 5 years, Teva Pharmaceutical Industries' Accumulated Depreciation & Amortization tumbled by 2176.69% in 2024 and then soared by 718.82% in 2025.
- Teva Pharmaceutical Industries' Accumulated Depreciation & Amortization (Quarter) stood at $5.2 billion in 2021, then grew by 5.29% to $5.5 billion in 2022, then rose by 2.16% to $5.6 billion in 2023, then fell by 21.77% to $4.4 billion in 2024, then rose by 7.19% to $4.7 billion in 2025.
- Its last three reported values are $4.7 billion in Q4 2025, $4.4 billion for Q4 2024, and $5.6 billion during Q4 2023.